Maravai Lifesciences Holdings, Inc.
A maker of the raw ingredients behind mRNA vaccines and therapies, Maravai LifeSciences supplies everything from its CleanCap® capping technology to impurity-detection kits used by biopharma and diagnostics companies in roughly sixty countries through its TriLink and Cygnus brands. Formed in 2014 by Carl Hull, Eric Tardif, and the private-equity firm GTCR, it grew by buying scientifically driven companies like TriLink and Cygnus. Its CleanCap® technology was a key ingredient in the Pfizer-BioNTech COVID-19 vaccine, and its name is the northern Italian word for "miracle."
Sold 9.94M
Granted 2.00M · Bought 466.8K
Granted 1.74M
Granted 649.8K
Granted 651.2K
Granted 156.1K · Bought 100.0K
Granted 500.0K
Granted 75.8K · Bought 175.0K
Granted 451.9K
Granted 412.2K
Granted 299.3K
Granted 464.2K · Sold 75.0K
Granted 584.1K
Granted 156.1K
Granted 156.1K · Bought 17.5K
Granted 109.8K
Granted 156.1K
Granted 156.1K
Granted 156.1K
Granted 109.8K
Granted 109.8K
Granted 20.6K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| GTCR Co-Invest XI LP +7 co-filersDirector, 10% owner · 3 transactions | — | 130.83Mas of May 2024 | — | — | 9.94M |
| Brust BerndChief Executive Officer, Director · 5 transactions | — | 2.12M | 2.00M | 466.8K | — |
| Martin William E. IIIChief Executive Officer · 5 transactions | +1412% | 1.81Mas of Mar 2025 | 1.74M | — | — |
| Leddy Peter MichaelSee Remarks · 9 transactions | +449.4% | 727.2Kas of Jul 2025 | 649.8K | — | — |
| Herde KevinChief Financial Officer · 11 transactions | +632.8% | 674.6Kas of May 2025 | 651.2K | — | — |
| Lucier Gregory TDirector · 11 transactions | — | 622.4K | 156.1K | 100.0K | — |
| Asarpota RajeshChief Financial Officer · 1 transaction | — | 500.0Kas of Jun 2025 | 500.0K | — | — |
| Hull CarlSee Remarks, Director · 4 transactions | — | 477.1Kas of Nov 2024 | 75.8K | 175.0K | — |
| Dolan ChristineSee Remarks · 15 transactions | +474.8% | 425.3K | 451.9K | — | — |
| Eckert R AndrewDirector · 3 transactions | — | 412.2K | 412.2K | — | — |
| Burch AndrewSee Remarks · 5 transactions | +161.8% | 369.2Kas of Jan 2025 | 299.3K | — | — |
| Oreshack KurtGeneral Counsel · 15 transactions | +429.9% | 335.8K | 464.2K | — | 75.0K |
| Buzzeo RebeccaSee Remarks · 7 transactions | +262.5% | 310.9Kas of Mar 2025 | 584.1K | — | — |
| Gray SusannahDirector · 3 transactions | +259.6% | 216.2K | 156.1K | — | — |
| DeFord John ADirector · 4 transactions | +544.1% | 205.5K | 156.1K | 17.5K | — |
| Hopfield JessicaDirector · 2 transactions | +121.8% | 199.9Kas of Jun 2025 | 109.8K | — | — |
| Cunningham Sean LaurenceDirector · 3 transactions | +552.1% | 184.3K | 156.1K | — | — |
| Marker Luke JosephDirector · 3 transactions | +552.1% | 184.3K | 156.1K | — | — |
| Mihas Constantine SDirector · 3 transactions | +552.1% | 184.3K | 156.1K | — | — |
| Prahalad MuraliDirector · 2 transactions | +244.9% | 154.6Kas of Jun 2025 | 109.8K | — | — |
| Daverman Benjamin JamesDirector · 2 transactions | +388.3% | 138.1Kas of Jun 2025 | 109.8K | — | — |
| Ashkenazi AnatDirector · 1 transaction | +51.5% | 60.8Kas of May 2024 | 20.6K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -9.26M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.